Knight Therapeutics (TSX:GUD) Cyclically Adjusted Book per Share: C$8.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:GUD Knight Therapeutics Inc TSX:GUD
73 GF Score
Price C$9.69
GF Value C$8.65
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Cyclically Adjusted Book per Share?

Knight Therapeutics TSX:GUD +0.10% 73 Cyclically Adjusted Book per Share is C$8.27 as of Mar. 2026. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$8.65 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Knight Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was C$8.013. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$8.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Knight Therapeutics's average Cyclically Adjusted Book Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-24), Knight Therapeutics's current stock price is C$9.69. Knight Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was C$8.27. Knight Therapeutics's Cyclically Adjusted PB Ratio of today is 1.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Knight Therapeutics was 1.20. The lowest was 0.58. And the median was 0.73.


Knight Therapeutics  (TSX:GUD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Knight Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.69/8.27
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Knight Therapeutics was 1.20. The lowest was 0.58. And the median was 0.73.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Knight Therapeutics Cyclically Adjusted Book per Share Related Terms


Knight Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Cyclically Adjusted Book per Share Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 7.55 7.95 8.15

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.08 8.14 8.16 8.15 8.27

TSX:GUD vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Cyclically Adjusted PB Ratio falls into.


TSX:GUD
73GF Score
Knight Therapeutics Inc TSX:GUD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Knight Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.013/132.2623*132.2623
=8.013

Current CPI (Mar. 2026) = 132.2623.

Knight Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 6.506 102.002 8.436
201609 6.553 101.765 8.517
201612 6.865 101.449 8.950
201703 6.888 102.634 8.876
201706 6.866 103.029 8.814
201709 6.867 103.345 8.789
201712 6.941 103.345 8.883
201803 7.012 105.004 8.832
201806 7.095 105.557 8.890
201809 7.143 105.636 8.943
201812 7.211 105.399 9.049
201903 7.228 106.979 8.936
201906 7.336 107.690 9.010
201909 7.065 107.611 8.683
201912 5.977 107.769 7.335
202003 5.870 107.927 7.194
202006 6.048 108.401 7.379
202009 6.768 108.164 8.276
202012 6.815 108.559 8.303
202103 6.557 110.298 7.863
202106 7.078 111.720 8.379
202109 7.138 112.905 8.362
202112 7.149 113.774 8.311
202203 7.118 117.646 8.002
202206 7.238 120.806 7.924
202209 7.499 120.648 8.221
202212 7.360 120.964 8.047
202303 7.439 122.702 8.019
202306 7.531 124.203 8.020
202309 7.806 125.230 8.244
202312 7.382 125.072 7.806
202403 7.530 126.258 7.888
202406 7.528 127.522 7.808
202409 7.664 127.285 7.964
202412 7.947 127.364 8.253
202503 7.999 129.181 8.190
202506 7.657 129.892 7.797
202509 7.693 130.287 7.810
202512 7.735 130.366 7.848
202603 8.013 132.262 8.013

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of C$8.27 mean?
Knight Therapeutics (TSX:GUD) has a Cyclically Adjusted Book per Share of C$8.27 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Cyclically Adjusted Book per Share too high?
Knight Therapeutics' current Cyclically Adjusted Book per Share is C$8.27. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Knight Therapeutics' Cyclically Adjusted Book per Share of C$8.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Cyclically Adjusted Book per Share is C$8.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Modestly Overvalued. The stock's GF Value™ is C$8.65, compared to a current price of C$9.69 — trading 12% above its estimated fair value. The current Cyclically Adjusted Book per Share is C$8.27. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Cyclically Adjusted Book per Share is C$8.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of C$9.69 is trading 12% above its estimated GF Value™ of C$8.65. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:GUD:

  • Cyclically Adjusted Book per Share: C$8.27
  • GF Value™: C$8.65 vs. price of C$9.69 (12% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges KHTRF:USA
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for TSX:GUD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.69
Price
C$8.65
GF Value